ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Sponsors

Lead sponsor: Eli Lilly and Company

Source Eli Lilly and Company
Brief Summary

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Overall Status Approved for marketing
Study Type Expanded Access
Condition
Intervention

Intervention type: Drug

Intervention name: Pemetrexed

Intervention type: Drug

Intervention name: Cisplatin

Eligibility

Criteria:

Inclusion Criteria:

- Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery

- Prior chemotherapy for your disease is allowed

- Measurable lesion is not required

- Have a adequate performance status

- Sign an informed consent form

Exclusion Criteria:

- You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study

- You are excluded from this trial if you have received radiation within the previous 2 weeks

- You are excluded from this trial if you are a candidates for curative surgery

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Location
facility
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. | Basking Ridge, New Jersey, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | Porto Alegre, RS, Brazil
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | Sao Paulo, Brazil
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." | Cairo, Egypt
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | Cairo, Egypt
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | Jeddah, Saudi Arabia
Location Countries

Brazil

Egypt

Saudi Arabia

United States

Verification Date

March 2007

Condition Browse
Source: ClinicalTrials.gov